Myostatin / Activin Pathway Research Muscle Growth & Performance

FLGR-242 (Follistatin)

An experimental follistatin-based research peptide investigated for its potential to inhibit myostatin, one of the body’s natural brakes on muscle growth.

Research note: FLGR-242-specific human pharmacokinetic, safety, and efficacy data remain limited. The broader follistatin/myostatin pathway is well characterized in preclinical research, but previous attempts to therapeutically manipulate it in humans have produced mixed clinical results.

What It Is

FLGR-242 is an experimental follistatin-based research peptide of interest because of its potential to influence the myostatin/activin pathway — one of the body’s primary regulatory systems for skeletal muscle growth. Myostatin (GDF-8) is a negative regulator of muscle mass, signaling through activin type II receptors to limit growth.

Follistatin works upstream by binding myostatin and other TGF-β superfamily members, helping prevent them from interacting with their receptors. The proposed research logic is: less myostatin signaling → less inhibition of muscle growth → more potential for hypertrophy. Follistatin isn’t selective only for myostatin, though — it also interacts with activins and other TGF-β ligands, which is why this pathway needs to be approached with more nuance than “a muscle-building peptide.”

Who May Benefit

  • Muscle growth and hypertrophy research
  • Preserving lean tissue during caloric restriction
  • Recovery from periods of muscle loss
  • Strength and performance research
  • Myostatin/activin pathway research
  • Long-term muscle preservation and healthy-aging research

What to Expect

Preclinical follistatin research has produced substantial muscle-mass increases in animal models, but translating those findings directly to humans is not established, and prior attempts to therapeutically target this pathway have shown mixed clinical results.

FLGR-242 specifically is a modified follistatin construct designed to alter circulation, binding, or biological activity relative to natural follistatin — it should not be assumed to behave identically to unmodified follistatin.

What to Pair It With

A direct growth-signaling approach that complements follistatin’s brake-removal mechanism.
GH secretagogues are commonly researched alongside follistatin-based compounds.
Another GH-axis angle commonly stacked with follistatin research per community protocols.

Reconstitution

Specific reconstitution figures for this compound weren’t included in the source material. Reconstitution ratios vary by vial size and intended concentration — use a peptide reconstitution calculator and consult your research protocol source before proceeding.

Suggested Research Dosing Strategy

Phase 1
2.5 mg every other week
For 6–8 weeks, per the source community protocol.
Phase 2 (if continuing)
2.5 mg per week
As a single weekly dose or split into 2–3 weekly injections on training days.
A more aggressive maintenance variant discussed in source material moves to 5 mg weekly (split into 2–3 injections) after 6 weeks. There is no FDA-approved human dosing protocol for FLGR-242 — treat any schedule strictly as an experimental research framework, not a validated recommendation. Always verify the actual vial concentration before calculating dosing, since different FLGR-242 products may differ.

Administration Notes

Reconstitute with 1 mL bacteriostatic water per the source protocol, adjusting for the actual labeled amount in the vial rather than assuming a standard concentration.

Because different FLGR-242 products may have different concentrations and formulations, always verify the vial’s actual amount before calculating dosing.

Research Considerations

Most anabolic research strategies focus on turning growth signals up; follistatin research instead looks at removing some of the body’s natural brakes on muscle growth — a fundamentally different mechanism.

The underlying follistatin/myostatin biology is legitimate and well studied preclinically, but FLGR-242 itself remains an experimental research compound, and human data are not yet at a point where it could be considered clinically established.

Pulse

Have a specific question about FLGR-242 (Follistatin)? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.
All Peptides by Goal